Description: Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is engaged in discovering and developing therapeutics for orphan indications. The company offers Glybera, a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Its product candidates in development comprise TV-45070, which is in Phase IIb clinical trials for the treatment of osteoarthritis of the knee; and in Phase II proof-of-concept clinical trials for the treatment of postherpetic neuralgia and Erythromelalgia. It is also developing TV-45070 for neuropathic pain indications; and GDC-0276 for the treatment of pain. The company's preclinical product candidates include a sodium channel inhibitor to treat DRAVET SYNDROME, an orphan disorder; XEN801, a stearoyl Co-A desaturase, an inhibitor for the treatment of acne; and small-molecule inhibitors for the treatment of cardiovascular disease. Xenon Pharmaceuticals Inc. has collaboration agreements with Teva Pharmaceutical Industries Ltd., Genentech, Inc., and Merck & Co., Inc. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Home Page: www.xenon-pharma.com
XENE Technical Analysis
3650 Gilmore Way
Burnaby,
BC
V5G 4W8
Canada
Phone:
604 484 3300
Officers
| Name | Title |
|---|---|
| Mr. Ian C. Mortimer C.M.A., CPA, CMA, CPA, M.B.A., MBA | Pres, CEO & Director |
| Ms. Sherry Aulin | Chief Financial Officer |
| Dr. Christopher John Kenney M.D. | Chief Medical Officer |
| Ms. Jodi Regts M.B.A., B.A., MBA | VP of Corp. Affairs & Investor Relations |
| Ms. Andrea DiFabio J.D. | Chief Legal Officer & Corp. Sec. |
| Ms. Shelley McCloskey B.A. | Exec. VP of HR |
| Dr. Robin P. Sherrington Ph.D. | Exec. VP of Strategy & Innovation |
| Dr. James R. Empfield Ph.D. | Exec. VP of Drug Discovery |
| Ms. Sheila M. Grant M.B.A., M.Sc., MBA | Exec. VP of R&D Operations |
| Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D. | Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.2172 |
| Price-to-Sales TTM: | 181.4446 |
| IPO Date: | 2014-11-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 149 |